Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2011 by Amgen.
Recruitment status was Active, not recruiting

Study NCT00626704 Information provided by Amgen

First Received on February 14, 2008. Last Updated on January 20, 2011 History of Changes

Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:

Conditions listed in this trial

Sarcoma
Soft Tissue Sarcoma

More general conditions related to this trial

Interventions listed in this trial

AMG 655
Placebo

Additional drug interventions recognized in this trial

Doxorubicin

More general drug interventions related to this trial

Sponsors listed in this trial

Amgen